ACT Genomics is a cancer solution provider and a reliable diagnostic partner in Asia. We offer precision medicine services through our locations in Taiwan, China, Hong Kong, Japan, and Singapore. Joint by experts from the field of cancer biology, cancer genomics, and bioinformatics, we provide cancer therapeutic recommendation, immunotherapy evaluation, treatment monitoring, as well as biomarker research through our integrated molecular diagnostic services. We utilize cutting-edge next-generation sequencing (NGS) technology and chip-based multiplex qPCR platform to turn complex genomic data into useful information for clinicians and pharmaceutical companies.
We provide comprehensive cancer diagnostic services in a CAP-accredited laboratory starting from clinical sample testing, bioinformatics analysis, to medical interpretation. With ACT Genomics’ strong presence in Asia, we can better support local and regional researches and clinical trials with faster turnaround time and more streamlined clinical operation. ACT Genomics is dedicated to providing meaningful insights into cancer treatment, drug development, and transforming cancer care.